Actively Recruiting
Amobarbital and Cardiopulmonary Bypass
Led by Tongji Hospital · Updated on 2025-03-21
80
Participants Needed
1
Research Sites
56 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Explore the effects of amobarbital on myocardial protection and prognosis in patients undergoing cardiac surgery with cardiopulmonary bypass, investigate the new usage of old drugs, and provide reliable clinical scientific basis for its potential value in better clinical treatment.
CONDITIONS
Official Title
Amobarbital and Cardiopulmonary Bypass
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 65 years old and scheduled for elective cardiac surgery with extracorporeal circulation
- American Society of Anesthesiologists (ASA) physical status II or III
- Surgery duration expected to be between 3 and 6 hours
- Signed informed consent form
You will not qualify if you...
- Body mass index (BMI) less than 18 kg/m2 or greater than 30 kg/m2
- History or potential history of drug abuse or alcohol dependence
- Preoperative use of sedatives or analgesics
- Severe liver or kidney dysfunction
- Allergy or potential allergy to barbiturates
- Coagulation dysfunction, endocrine disorders, or other conditions affecting blood circulation
- Participation in other clinical studies within the past 3 months
- Considered unsuitable for participation by the researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tongji hospital
Wuhan, Hubei, China, 430030
Actively Recruiting
Research Team
M
mujun chang, Dr
CONTACT
P
Pu zhou, Dr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here